feedback knee implant
result industri contact
surpris magnitud downturn knee implant
organ growth report april year-over-year
versu year-over-year declin reach
industri contact discuss thought situat
industri contact attribut half step-down jnj knee
organ growth softer market condit flat slightli year-over-year
includ sale day chang accord industri contact versu
year-over-year addit better understood competit
pressur portfolio gap cementless knee robot versu
contact also believ increment surgeon concern regard perform
attun primari knee system magnitud depuy
leadership team turnov weigh domest knee implant sale
written concern regard attun clinic perform
recent note acknowledg case
tibial loosen attun compani continu point intern
registri data support belief attun clinic result fine said
contact suggest surgeon concern attun get louder
believ worri impact jnj knee implant sale
updat forecast sole jnj report result reduc
world-wide hip knee implant organ growth estim flat neg
given industri contact feedback market weak result
orthoped practic survey feel comfort make
chang reduc organ growth outlook ad million
organ growth dollar competitor hip knee implant segment
get back prior flat organ growth estim market said
increment optimist attun challeng could potenti lead
addit opportun market share gain joint replac compani
within coverag group later year view increment posit
given product portfolio advantag lesser extent snn
addit continu expect achiev
upsid versu consensu among joint replac compani coverag
group note revenu adjust ep estim
million million consensu respect
import pleas read disclosur disclaim page report
smith nephew plcannual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg net interest incom financ result profit incom tax incom margin incom margin adr wghd averag share adr adr revenu growth adjust ep growth compani report northcoast research estim
stryker corporationannu incom statement analysi adjust northcoast research million except percentag per share gross gross sg intang oper oper net interest incom incom tax incom extra incom extra extra net net wghd com share ep ep growth ep growth start exclud acquistion-rel intang amort expens adjust ep compani report northcoast research estim
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
research produc northcoast research partner llc northcoast research member finra www finra org sipc www sipc org
research institut investor use although believ inform obtain reliabl sourc dont guarante
accuraci may incomplet condens past perform indic futur result chang assumpt may
materi effect project result
buy stock expect outperform index twelve-month period
neutral stock expect perform in-lin index twelve-month period
sell stock expect under-perform index twelve-month period
valuat risk
price target well recommend base time horizon howev guarante investor achiev
result use varieti method determin price target individu secur includ fundament analysi addit
employ numer valuat methodolog includ limit price earn multipl enterpris valu earn
interest tax depreci amort ebitda book valu free cash flow yield discount cash flow rel valuat secur
subject variou risk factor pleas refer text recent report specif compani valuat price target
rate price target histori smith nephew plc snn
rate price target histori corp
creat bluematrix
creat bluematrix
rate price target histori inc
creat bluematrix
distribut rate tabl
david keiser certifi view opinion express research report accur reflect person view secur
issuer mention report certifi part compens directli indirectli relat
specif recommend view contain report analyst compens base qualiti analysi commun skill
matter polici practic northcoast research prohibit offer favor research specif rate specif target price
consider induc receipt busi compens addit associ person prepar research report
prohibit own secur subject compani
